Information Provided By:
Fly News Breaks for August 29, 2019
DOVA
Aug 29, 2019 | 07:24 EDT
As previously reported, Oppenheimer analyst Justin Kim started coverage of Dova Pharmaceuticals with an Outperform rating and $30 price target. In the midst of a commercial expansion into chronic immune thrombocytopenia, the analyst views the company's Doptelet - a thrombopoietin receptor agonist, treating plateletrelated deficiencies - as a best-in-breed therapy for an already defined commercial market. In the $1B U.S. ITP market alone, Kim believes strong commercial execution could re-rate the shares.
News For DOVA From the Last 2 Days
There are no results for your query DOVA